Member Info for Dr_DMS

Genesig Kit Catalogue page 10 specifically states Bundibugyo variant is available

They do have testing kits for this strain, stop telling lies

The board only own about 15.5% so i think they are putting it to the institutions now...?

Why no RNS?

WB - considering you have so much invested here (?) you continually deramp the share, nobody would do that if they had what you said.....!

I'm surprised they have 230 people working there, what the hell are they doing?!!!

Novacyt confirmed it possesses dedicated filovirus qPCR platforms and primer-designed assays explicitly equipped to detect the Bundibugyo strain.

Here we go.....

https://www.msn.com/en-gb/health/other/england-world-cup-base-hit-by-ebola-health-alert-as-deadly-disease-becomes-visible-fast/ar-AA24ipkp?ocid=msedgntp&pc=ASTS&cvid=6a180e97f7094305b23aa1b0fa073fcb&cvpid=17a885321548477291d70b112802bd22&ei=6

21st August

Yes, now fully owned by NCYT, those margins should go up to 60% easily

Yeh plus the Australian market is opening up rapidly, reimbursing, and they now have SCDiagnostics....

Could be a super spreader event

It was probably WBAFC having a top up...

Bcos ive been in 6 yrs and they still say the same crap about commercials, have you tried it for that long?

Listened to half then got bored, same old crap, was anything said?

??

Defo a buy

Hmmmmmm.....

I don't think the PGX covers chemo does it?

IVDR Compliance: With the enforcement of the European Union's In Vitro Diagnostic Regulation (IVDR), manufacturers must provide robust, clinical evidence supporting the safety and validity of their diagnostic kits. Consequently, industry players like Novacyt/Yourgene Health have driven market growth by securing IVDR certification for their specialized DPYD assays.

Key Providers: Major players in this market offer targeted SNP detection (Single Nucleotide Polymorphisms) or sequencing assays. Prominent companies in the space include Yourgene Health (Novacyt), Roche (LightMix kits), Tempus, and LGC Clinical Diagnostics, which also produces mutation controls.

Test Economics: The retail cost of an individual DPYD genetic test generally ranges between \(\$100\) and \(\$300\), yielding an excellent cost-to-value ratio for oncology departments and pathology labs